Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Chemotherapy Options for Patients with Relapsed Epithelial Ovarian Cancer

Chemotherapy Options for Patients with Relapsed Epithelial Ovarian Cancer Epithelial ovarian cancer (EOC) is the most common cause of death from gynecological malignancy in the industrialized world. Most patients present with advanced disease and, despite optimal surgical debulking and front-line chemotherapy with platinum- and taxane-based regimens, the majority will relapse. Relapsed EOC is incurable but there are various palliative treatment options. Patients who relapse more than 12 months after primary treatment have a good chance of response to re-challenge with platinum-based chemotherapy. Disease bulk, number of sites of disease, serous histology, type of chemotherapy, baseline hemoglobin, performance status, response to last chemotherapy, and presence of liver metastases also predict treatment outcome in relapsed disease. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Chemotherapy Options for Patients with Relapsed Epithelial Ovarian Cancer

American Journal of Cancer , Volume 1 (3) – Aug 9, 2012

Loading next page...
 
/lp/springer-journals/chemotherapy-options-for-patients-with-relapsed-epithelial-ovarian-yacfIKEvn0
Publisher
Springer Journals
Copyright
Copyright © 2002 by Adis International Limited
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200201030-00005
Publisher site
See Article on Publisher Site

Abstract

Epithelial ovarian cancer (EOC) is the most common cause of death from gynecological malignancy in the industrialized world. Most patients present with advanced disease and, despite optimal surgical debulking and front-line chemotherapy with platinum- and taxane-based regimens, the majority will relapse. Relapsed EOC is incurable but there are various palliative treatment options. Patients who relapse more than 12 months after primary treatment have a good chance of response to re-challenge with platinum-based chemotherapy. Disease bulk, number of sites of disease, serous histology, type of chemotherapy, baseline hemoglobin, performance status, response to last chemotherapy, and presence of liver metastases also predict treatment outcome in relapsed disease.

Journal

American Journal of CancerSpringer Journals

Published: Aug 9, 2012

References